{"gene":"BATF2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2008,"finding":"BATF2/SARI is an IFN-beta-inducible gene that interacts with c-Jun via its leucine zipper domain, inhibiting DNA binding of the AP-1 complex and consequently suppressing AP-1-dependent gene expression; overexpression induces apoptosis in cancer cells but not normal cells.","method":"Co-immunoprecipitation (leucine zipper interaction with c-Jun), AP-1 reporter assays, antisense knockdown, overexpression in cancer vs. normal cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, reporter assay, antisense KD, functional rescue) in a single foundational study, replicated conceptually in multiple subsequent papers","pmids":["19074269"],"is_preprint":false},{"year":2010,"finding":"BATF2/SARI inhibits AP-1 transactivation by interacting with c-Jun and directly suppresses CCN1 promoter activity; SARI overexpression reduces CCN1-promoter AP-1 binding and inhibits anchorage-independent growth and tumor cell invasion.","method":"Adenoviral overexpression (Ad.SARI), promoter-activity luciferase assays, AP-1 binding assays, stable c-Jun-overexpressing rat embryo fibroblast epistasis model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (promoter assay, AP-1 binding, genetic epistasis), single lab","pmids":["20531301"],"is_preprint":false},{"year":2015,"finding":"BATF2 forms a complex with IRF1; Co-IP demonstrated this association, and IRF1 knockdown down-regulated IFN-γ- or LPS-activated host-protective genes (Tnf, Ccl5, Il12b, Nos2), indicating BATF2/IRF1 co-regulation of M1 macrophage inflammatory gene expression.","method":"Co-immunoprecipitation, siRNA knockdown, expression profiling, promoter motif enrichment analysis","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional knockdown with defined gene-expression phenotype, single lab but multiple orthogonal methods","pmids":["25957166"],"is_preprint":false},{"year":2015,"finding":"BATF2 overexpression inhibits HGF/MET signaling in colorectal cancer cells, suppressing proliferation, migration, and invasion; MET inhibitors combined with IFN-β produced synergistic cytotoxicity in vitro and in vivo.","method":"Overexpression in cultured CRC cells, xenograft tumor models, in vitro/in vivo combination treatment assays","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and xenograft functional assays with defined signaling pathway, single lab","pmids":["25762344"],"is_preprint":false},{"year":2016,"finding":"BATF2/SARI directly interacts with ceruloplasmin (Cp) and induces its protease degradation, thereby inhibiting the HIF-1α/VEGF axis and suppressing tumor angiogenesis.","method":"Co-IP/PAGE/mass spectrometry, HUVEC angiogenesis assays, antibody arrays, in vivo AOM/DSS tumor model in SARI-deficient mice","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Co-IP/MS for direct interaction identification, multiple functional assays in vitro and in vivo with genetic knockout model","pmids":["27353863"],"is_preprint":false},{"year":2013,"finding":"BATF2/SARI expression is necessary for mda-7/IL-24 anti-tumor effects; MDA-7/IL-24 induces SARI through p38 MAPK phosphorylation, and inhibition of p38 MAPK blocks SARI induction; secreted MDA-7/IL-24 induces its own expression via an autocrine loop involving SARI.","method":"SARI antisense inhibition, adenoviral overexpression, p38 MAPK inhibitor experiments, recombinant MDA-7/IL-24 stimulation, receptor binding studies","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antisense loss-of-function plus pharmacological pathway inhibition, single lab","pmids":["24282278"],"is_preprint":false},{"year":2017,"finding":"BATF2 interacts with NF-κB p50/p65 subunits and promotes IL-12 p40 expression in macrophages; BATF2-deficient macrophages produce significantly less IL-12 p40 upon TLR ligand stimulation, reducing CD8+ T cell activation within tumors.","method":"Co-immunoprecipitation (BATF2 with p50/p65), Batf2-/- mouse model, in vitro macrophage stimulation assays, subcutaneous tumor model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus Batf2 KO mouse model with defined immune phenotype, replicated in vitro and in vivo","pmids":["28808017"],"is_preprint":false},{"year":2017,"finding":"BATF2 interacts with c-JUN and prevents c-JUN–ATF-2 complex formation in innate immune cells, thereby inhibiting Il23a expression and suppressing IL-17-mediated immunopathology during T. cruzi infection.","method":"Batf2-/- mouse infection model, co-immunoprecipitation (BATF2/c-JUN), cytokine measurement, T cell transfer experiments","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP for mechanism plus Batf2 KO mouse model with defined immunological phenotype and rescue experiments","pmids":["28356392"],"is_preprint":false},{"year":2016,"finding":"Glucocorticoid receptor (GR) directly binds the ER9 element in the SARI promoter region, activating SARI transcription; SARI upregulation is necessary for dexamethasone-mediated growth suppression and AP-1 inhibition in B lymphoma cells.","method":"EMSA, ChIP assays, reporter assays, SARI siRNA knockdown, in vitro and in vivo dexamethasone treatment","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — EMSA and ChIP establish direct GR-promoter binding; functional knockdown confirms necessity; multiple orthogonal methods, single lab","pmids":["26808579"],"is_preprint":false},{"year":2020,"finding":"BATF2 binds p53 protein and enhances its stability, thereby inhibiting ERK phosphorylation in gastric cancer cells; additionally, METTL3-mediated m6A modification of BATF2 mRNA represses BATF2 expression in gastric cancer.","method":"Co-immunoprecipitation (BATF2-p53), Western blotting for p53 stability and p-ERK levels, m6A modification assays, in vitro and in vivo functional experiments","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and protein stability assays plus pathway inhibition, single lab","pmids":["32650804"],"is_preprint":false},{"year":2019,"finding":"BATF2 suppresses the STAT1/MCP-1/CCR2 axis in colon cancer cells: SARI deficiency increases p-STAT1 and STAT1 expression, promotes MCP-1 secretion, and enhances tumor-associated macrophage infiltration during colitis-associated cancer.","method":"SARI-deficient mouse model, bone marrow reconstitution, Western blotting for p-STAT1, functional tumor macrophage infiltration assays","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO mouse plus mechanistic Western blotting, single lab","pmids":["31578820"],"is_preprint":false},{"year":2019,"finding":"BATF2 targets PAI-1 (plasminogen activator inhibitor-1), as shown by Co-IP and luciferase assays; BATF2 induction by calycosin suppresses TGF-β-induced EMT and cell migration via the Wnt and PI3K/Akt signaling pathways in CRC cells.","method":"Co-immunoprecipitation, luciferase reporter assays, Transwell migration assays, Western blotting","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP and reporter assays establish BATF2-PAI-1 interaction, functional migration assays, single lab","pmids":["31174572"],"is_preprint":false},{"year":2019,"finding":"BATF2 overexpression suppresses Wnt/β-catenin signaling and reverses multidrug resistance in gastric cancer cells; knockdown of β-catenin mimics BATF2 effects, and restoration of Wnt/β-catenin activity reverses BATF2-mediated drug sensitization.","method":"Overexpression/knockdown systems, Wnt/β-catenin reporter (TOP/FOP FLASH implied), Western blotting, MTT assay, flow cytometry","journal":"In vitro cellular & developmental biology. Animal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — epistasis via β-catenin knockdown rescue, Western blot pathway analysis, single lab","pmids":["31140101"],"is_preprint":false},{"year":2012,"finding":"Loss of SARI/BATF2 expression initiates epithelial-mesenchymal transition (EMT) in lung adenocarcinoma, characterized by repression of E-cadherin and upregulation of vimentin; SARI regulates EMT through the GSK-3β/β-catenin signaling pathway.","method":"SARI knockdown in human carcinoma cells, xenograft mouse model for lymph node metastasis, Western blotting for EMT markers and pathway components","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with defined EMT phenotype and pathway component analysis, in vivo xenograft validation, single lab","pmids":["23049725"],"is_preprint":false},{"year":2018,"finding":"BATF2 and STAT1 expression are mutually dependent in trophoblast cells; BATF2 silencing increases invasion, and both BATF2 and STAT1 regulate phospho-JUN expression, jointly mediating IFN-γ-induced inhibition of HTR-8/SVneo trophoblast invasion.","method":"siRNA knockdown of BATF2 and STAT1, Transwell invasion assays, NGS expression profiling, Western blotting","journal":"Cell adhesion & migration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with defined invasion phenotype and mutual dependency established, single lab","pmids":["29394132"],"is_preprint":false},{"year":2023,"finding":"BATF2 nuclear export is mediated through a functional nuclear export sequence (NES) that binds CRM1 (exportin-1); cytoplasmic BATF2 is subsequently targeted for ubiquitin-mediated degradation and enhances CRC growth via AP-1/cyclin D1/pRb signaling. Mutation of NES or CRM1 knockdown retards export and suppresses tumor growth.","method":"Co-IP, quantitative label-free LC-MS/MS proteomics, Western blotting, immunofluorescence, point mutation of NES, siRNA knockdown of CRM1, xenograft nude mice","journal":"Clinical and translational medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Co-IP/MS for binding partner identification, NES mutagenesis establishing functional site, CRM1 KD rescue, in vivo validation; multiple orthogonal methods","pmids":["37151195"],"is_preprint":false},{"year":2023,"finding":"BATF2 forms a complex with JUN in hematopoietic stem cells (HSCs) to amplify pro-inflammatory signaling including CCL5; CCL5 receptor blockade phenocopies Batf2 KO myeloid differentiation defects, and recombinant CCL5 rescues IFN-γ-induced myeloid differentiation in Batf2 KO mice.","method":"Co-IP (BATF2-JUN complex), Batf2 KO mouse model during chronic infection, CCL5 receptor blockade/recombinant CCL5 rescue experiments","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP plus genetic KO with pharmacological rescue, replicated in vivo and in vitro, multiple methods","pmids":["36824275"],"is_preprint":false},{"year":2023,"finding":"Induction of BATF2 expression in macrophages by Klebsiella pneumoniae requires TRIF and type I interferon signaling but not MyD88; BATF2 markedly enhances macrophage pro-inflammatory cytokine responses and contributes to early host defense against pulmonary infection.","method":"TRIF-/-, MyD88-/-, type I IFN signaling-deficient macrophage experiments in vitro; Batf2-/- mouse Kp infection model","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic pathway dissection using multiple KO cell lines/mice, in vivo Batf2-/- model with bacterial burden and cytokine phenotype","pmids":["37724373"],"is_preprint":false},{"year":2025,"finding":"BATF2 binds regulatory regions of cell cycle genes (CDKR1B/p27, CDK2, cyclin D1) in astrocytes as determined by ChIP-seq; BATF2 loss increases expression of these targets and increases proliferation markers (Ki67, phospho-histone H3), establishing BATF2 as a cell cycle suppressor in astrocytes.","method":"Chromatin immunoprecipitation sequencing (ChIP-seq), BATF2 KO astrocytes, Western blotting for proliferation markers, patient-derived glioblastoma sample analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP-seq establishes direct genomic binding with loss-of-function confirmation of target gene upregulation, multiple orthogonal methods","pmids":["40945729"],"is_preprint":false},{"year":2025,"finding":"In astrocytes, BATF2 binds and prevents overexpression of IRF1 and IRF1 targets (e.g., caspase-1) as shown by ChIP-seq; Batf2-/- mice show exacerbated CNS autoimmune disease severity with increased astrocyte IRF1 and caspase-1 expression.","method":"ChIP-seq, Batf2-/- mouse EAE model, immunofluorescence in MS patient lesions, Western blotting","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP-seq for direct binding plus Batf2 KO mouse model with defined neuro-inflammatory phenotype and human tissue validation","pmids":["40057949"],"is_preprint":false},{"year":2025,"finding":"BATF2 phosphorylation at serine 227 promotes oligomerization of STING; BATF2 deficiency or high glutamine levels result in higher oxygen consumption rates and metabolic profiles unfavorable for type I interferon production; cancer cell-specific BATF2 expression promotes a type-I IFN-dependent anti-tumor response.","method":"Phosphorylation site mutational analysis, STING oligomerization assays, metabolic profiling, syngeneic orthotopic and carcinogen-induced HNSCC models with Batf2-/- mice","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-site mutagenesis and STING oligomerization established; metabolic and in vivo data, single study","pmids":["41457098"],"is_preprint":false},{"year":2021,"finding":"BATF2 inhibits SDF-1α/CXCL12 expression intracellularly, reducing its loading into extracellular vesicles; BATF2-containing EVs inhibit MDSC chemotaxis in vitro, and blocking SDF-1α/CXCR4 signaling phenocopies BATF2 overexpression in reducing MDSC recruitment to glioblastoma.","method":"BATF2 overexpressing glioma cell EV isolation, in vitro MDSC chemotaxis assays, AMD3100 (CXCR4 antagonist) blockade, Western blotting for SDF-1α","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological blockade phenocopies BATF2 OE; EV-based mechanism, functional chemotaxis assay; single lab","pmids":["33452462"],"is_preprint":false},{"year":2021,"finding":"BATF2/SARI induces cancer-specific cell death in OSCC by inhibiting GLI1 expression through induction of endoplasmic reticulum (ER) stress; an ER stress inhibitor reverses SARI-mediated tumor growth inhibition in vivo.","method":"Adenoviral SARI overexpression (Ad.SARI), confocal microscopy for ER stress markers, ER stress inhibitor rescue, xenograft nude mouse model","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ER stress pathway placement via pharmacological inhibitor rescue in vitro and in vivo, single lab","pmids":["34774620"],"is_preprint":false},{"year":2024,"finding":"BATF2 interacts with SINHCAF and together they regulate TTC23 transcription; this regulation modulates macrophage quantity and anti-bacterial/antigen-presenting function during Mycobacterium tuberculosis infection through the Wnt/β-catenin pathway.","method":"Co-immunoprecipitation (BATF2-SINHCAF), TTC23 knockdown/overexpression, Wnt/β-catenin pathway inhibition, macrophage functional assays","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP establishes BATF2-SINHCAF complex; functional pathway placement via KD, single lab","pmids":["39672395"],"is_preprint":false},{"year":2025,"finding":"BATF2 transcriptionally regulates RGS2 in CD8+ T cells; BATF2 KO mice show increased effector CD8+ T cells and reduced exhausted T cells; luciferase reporter assays confirmed BATF2 as a transcriptional activator of RGS2, promoting T cell exhaustion through inhibition of CXCL13 secretion.","method":"Luciferase reporter assays for RGS2 promoter, BATF2-/- and RGS2-/- mouse tumor models, single-cell transcriptomics, CD8+ T cell co-culture cytotoxicity assays","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter establishes transcriptional regulation; KO mouse models with defined immune phenotype; single lab","pmids":["40442751"],"is_preprint":false},{"year":2022,"finding":"METTL14-mediated m6A modification of BATF2 mRNA suppresses BATF2 expression in tongue squamous cell carcinoma; BATF2 suppresses tumor angiogenesis by inhibiting VEGFA expression.","method":"m6A methylation assays, METTL14 knockdown/overexpression, Western blotting for VEGFA, angiogenesis assays in TSCC cell lines","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — m6A writer identified and functional VEGFA downstream target established; single lab","pmids":["35949109"],"is_preprint":false},{"year":2024,"finding":"BATF2 inhibits ABCG2 drug transporter expression and promotes PTEN stability, suppressing AKT phosphorylation, reducing nuclear β-catenin, and decreasing stem cell markers (CD44, SOX2, NANOG) to reduce chemoresistance in gastric cancer.","method":"BATF2 overexpression/KD in GC cells and organoids, Western blotting for PTEN/AKT/β-catenin pathway, ABCG2 expression assays, in vivo subcutaneous tumor model, scRNA-seq","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway components analyzed with OE/KD, in vivo validation, single lab","pmids":["39629124"],"is_preprint":false},{"year":2023,"finding":"Loss-of-function homozygous BATF2 mutation (p.Gln19*) in humans causes dysregulation of interferon-stimulated genes and elevated innate immune responses; CRISPR-Cas9 BATF2-/- human monocytic cell lines recapitulate elevated responses to innate immune stimuli.","method":"Whole-exome sequencing, transcriptome analysis, CRISPR-Cas9 BATF2-/- human monocytic cell lines, stimulation assays","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — human genetics plus CRISPR KO cell line functional validation, transcriptomic phenotyping; multiple orthogonal methods","pmids":["36672163"],"is_preprint":false},{"year":2025,"finding":"BATF2 stabilizes ATF3 by inhibiting its ubiquitination; BATF2 overexpression impairs mitochondrial redox homeostasis in nucleus pulposus cells, promoting apoptosis and ECM catabolism; ATF3 knockdown reverses BATF2-induced mitochondrial dysfunction.","method":"Ubiquitination assays for ATF3, BATF2 overexpression/KD in nucleus pulposus cells, mitochondrial function assays, ATF3 siRNA rescue, in vivo disc degeneration model","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay establishes post-translational mechanism; ATF3 KD rescue confirms pathway placement; single lab","pmids":["40267724"],"is_preprint":false},{"year":2016,"finding":"BATF2 overexpression drives transcription of centromeric type II satellite DNA; ChIP-seq identified a specific DNA binding motif (TTCCATT[CT]GATTCCATTC[AG]AT) primarily distributed among chromosome centromere regions.","method":"Stable BATF2 transfection in HeLa cells, ChIP-sequencing, bioinformatics motif analysis, satellite DNA transcription assays","journal":"Anticancer research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — ChIP-seq establishes genomic binding motif; single lab, single method study","pmids":["26977016"],"is_preprint":false},{"year":2021,"finding":"BATF2 promotes Th1 and Treg cell differentiation but suppresses Th17 cell activation in CD4+ T cells; BATF2 mRNA is increased under Th1 and Treg polarization conditions but decreased under Th17 polarization.","method":"siRNA knockdown of BATF2 in human CD4+ T cells, cytokine polarization conditions, flow cytometry for T cell subsets","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with defined T cell polarization phenotype; single lab","pmids":["33740622"],"is_preprint":false},{"year":2024,"finding":"ABBV-744 (BD2-selective BET inhibitor) reduces BATF2 and IRF4 expression and suppresses JAK-STAT signaling in LPS-stimulated microglia; gene knockdown of BATF2 confirmed BATF2 is required for the BATF2-IRF4-STAT1/3/5 pathway regulation of microglial inflammation.","method":"RNA-seq, BATF2/IRF4 siRNA knockdown, Western blotting for STAT1/3/5, in vitro BV-2 and primary microglia models, in vivo mouse LPS model","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene KD confirmation of pathway; RNA-seq; single lab","pmids":["38862817"],"is_preprint":false},{"year":2023,"finding":"BATF2 inhibits PD-L1 expression in cancer cells by inhibiting the PI3K-AKT pathway, with ZEB2 playing an important role in this process; BATF2 promotes CD8+ T cell infiltration and activation in non-small cell lung cancer.","method":"BATF2 KO mice, human xenograft mice, RT-qPCR, Western blotting, bioinformatics analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse plus xenograft model with defined pathway; single lab","pmids":["37777155"],"is_preprint":false}],"current_model":"BATF2 (also known as SARI) is an IFN-β/IFN-γ-inducible basic leucine zipper transcription factor that acts as a tumor suppressor and immune regulator: it suppresses AP-1 activity by interacting with c-Jun via its leucine zipper domain, forms functional complexes with IRF1, NF-κB (p50/p65), and JUN to regulate macrophage inflammatory gene programs (including IL-12p40, TNF, CCL5, NOS2), undergoes nuclear export via a CRM1-dependent NES sequence followed by ubiquitin-mediated degradation in cancer cells, binds and stabilizes p53 to inhibit ERK signaling, promotes STING oligomerization when phosphorylated at Ser227, directly targets ceruloplasmin for degradation to inhibit the HIF-1α/VEGF angiogenic axis, and is transcriptionally regulated by glucocorticoid receptor binding to its promoter and post-transcriptionally silenced by METTL3/METTL14-mediated m6A modification; in innate immune cells it suppresses IL-23 production by preventing c-JUN–ATF2 complex formation, and in astrocytes it binds IRF1 regulatory regions to prevent overactive IFN signaling and controls cell cycle gene expression including cyclin D1, CDK2, and p27."},"narrative":{"mechanistic_narrative":"BATF2 (SARI) is an interferon-inducible basic leucine zipper transcription factor that functions as a tumor suppressor and an immune regulator by reprogramming AP-1-dependent and interferon-dependent gene expression [PMID:19074269, PMID:25957166]. Its founding activity is antagonism of AP-1: BATF2 binds c-Jun through its leucine zipper domain, blocking AP-1 DNA binding and transactivation, repressing AP-1 targets such as CCN1, and triggering cancer-cell-selective apoptosis [PMID:19074269, PMID:20531301]. In innate immune cells BATF2 partners with transcriptional and signaling factors to shape inflammatory output — it complexes with IRF1 to co-regulate M1 macrophage genes (Tnf, Ccl5, Il12b, Nos2), with NF-κB p50/p65 to drive IL-12p40 and CD8+ T cell activation, and with JUN to amplify pro-inflammatory CCL5 signaling, while preventing c-JUN–ATF2 complex formation to restrain Il23a and IL-17-mediated immunopathology [PMID:25957166, PMID:28808017, PMID:28356392, PMID:36824275]. Its induction in macrophages is interferon-driven, requiring TRIF and type I IFN signaling, and human loss-of-function (p.Gln19*) dysregulates interferon-stimulated genes [PMID:37724373, PMID:36672163]; in astrocytes BATF2 directly occupies IRF1 regulatory regions by ChIP-seq to prevent overactive IFN signaling and protect against CNS autoimmunity [PMID:40057949]. Beyond transcriptional partnerships, BATF2 acts post-translationally — it directly binds ceruloplasmin and drives its degradation to suppress the HIF-1α/VEGF angiogenic axis, binds and stabilizes p53 to inhibit ERK signaling, and when phosphorylated at Ser227 promotes STING oligomerization to favor a type-I-IFN-dependent anti-tumor response [PMID:27353863, PMID:32650804, PMID:41457098]. As a sequence-specific factor BATF2 binds defined genomic motifs and represses cell-cycle genes (cyclin D1, CDK2, p27) in astrocytes [PMID:40945729, PMID:26977016]. BATF2 protein abundance is itself controlled: glucocorticoid receptor binds the SARI promoter to activate transcription, while m6A modification by METTL3/METTL14 silences BATF2 mRNA in gastric and tongue cancers, and a CRM1-dependent NES drives nuclear export followed by ubiquitin-mediated degradation in colorectal cancer [PMID:26808579, PMID:32650804, PMID:37151195, PMID:35949109].","teleology":[{"year":2008,"claim":"Established BATF2's founding molecular activity — that an IFN-inducible bZIP factor antagonizes AP-1 — answering how it could act as a tumor suppressor.","evidence":"Co-IP of leucine-zipper interaction with c-Jun, AP-1 reporter assays, antisense knockdown and overexpression in cancer versus normal cells","pmids":["19074269"],"confidence":"High","gaps":["Did not define direct genomic targets of BATF2 itself","Mechanism of cancer-cell-selective apoptosis unresolved"]},{"year":2010,"claim":"Connected AP-1 antagonism to a specific target promoter and tumor phenotype, showing BATF2 suppresses CCN1 and anchorage-independent growth.","evidence":"Adenoviral overexpression, CCN1 promoter luciferase and AP-1 binding assays, c-Jun-overexpressing fibroblast epistasis","pmids":["20531301"],"confidence":"High","gaps":["Whether CCN1 repression is direct or via AP-1 sequestration not separated"]},{"year":2012,"claim":"Showed loss of BATF2 promotes EMT and metastasis via GSK-3β/β-catenin, framing it as a metastasis suppressor.","evidence":"Knockdown in carcinoma cells, xenograft lymph node metastasis model, EMT marker Western blotting","pmids":["23049725"],"confidence":"Medium","gaps":["No direct evidence BATF2 regulates GSK-3β/β-catenin components transcriptionally","Single lab"]},{"year":2015,"claim":"Identified IRF1 as a transcriptional partner, establishing BATF2 as a co-regulator of the M1 macrophage inflammatory program.","evidence":"Co-IP, siRNA knockdown, expression profiling and promoter motif enrichment in macrophages","pmids":["25957166"],"confidence":"High","gaps":["DNA-binding contribution of BATF2 versus IRF1 at target promoters not dissected"]},{"year":2016,"claim":"Revealed a non-transcriptional mechanism — direct binding and degradation of ceruloplasmin — linking BATF2 to suppression of the HIF-1α/VEGF angiogenic axis.","evidence":"Co-IP/MS, HUVEC angiogenesis assays, antibody arrays, AOM/DSS tumor model in SARI-deficient mice","pmids":["27353863"],"confidence":"High","gaps":["Protease responsible for ceruloplasmin degradation not identified","How a nuclear bZIP factor reaches ceruloplasmin unclear"]},{"year":2016,"claim":"Defined upstream transcriptional control by glucocorticoid receptor, explaining how steroid signaling induces BATF2 to suppress growth.","evidence":"EMSA and ChIP showing GR binding to the SARI promoter ER9 element, reporter assays, siRNA knockdown with dexamethasone treatment","pmids":["26808579"],"confidence":"High","gaps":["Whether GR induction of BATF2 occurs outside B lymphoma cells not tested"]},{"year":2016,"claim":"Provided the first direct genomic binding map, showing BATF2 recognizes a centromeric satellite-associated motif.","evidence":"Stable transfection in HeLa, ChIP-seq and motif analysis","pmids":["26977016"],"confidence":"Medium","gaps":["Functional consequence of satellite DNA transcription unclear","Single-method study"]},{"year":2017,"claim":"Established two distinct immune partnerships: NF-κB-dependent promotion of IL-12p40 anti-tumor immunity and JUN-dependent restraint of pathogenic IL-23/IL-17.","evidence":"Co-IP with p50/p65 and with c-JUN, Batf2-/- mice, macrophage stimulation, tumor and T. cruzi infection models","pmids":["28808017","28356392"],"confidence":"High","gaps":["How BATF2 switches between activating (NF-κB) and repressive (JUN/ATF2) modes not defined"]},{"year":2020,"claim":"Identified p53 stabilization as a mechanism of ERK inhibition and revealed m6A as a post-transcriptional silencing layer in gastric cancer.","evidence":"Co-IP, p53 stability and p-ERK Western blotting, m6A modification assays in gastric cancer","pmids":["32650804"],"confidence":"Medium","gaps":["Direct vs. indirect link between p53 binding and ERK suppression unresolved","Single lab"]},{"year":2023,"claim":"Defined nuclear export and degradation as the route to BATF2 inactivation in cancer, identifying CRM1 as the export receptor.","evidence":"Co-IP/LC-MS proteomics, NES point mutation, CRM1 knockdown, immunofluorescence, xenografts","pmids":["37151195"],"confidence":"High","gaps":["E3 ligase mediating cytoplasmic BATF2 degradation not identified"]},{"year":2023,"claim":"Connected human BATF2 loss-of-function to dysregulated interferon-stimulated gene control, establishing a physiological brake on innate immunity.","evidence":"Whole-exome sequencing of p.Gln19* patients, CRISPR-Cas9 BATF2-/- human monocytic lines with stimulation assays","pmids":["36672163"],"confidence":"High","gaps":["Clinical disease spectrum of the mutation not fully delineated","Direct ISG targets in human cells not mapped"]},{"year":2023,"claim":"Showed interferon-pathway dependence of BATF2 induction (TRIF/type I IFN, not MyD88) and a JUN-CCL5 axis amplifying inflammation in hematopoietic cells.","evidence":"TRIF/MyD88/IFN-deficient macrophages, Co-IP of BATF2-JUN, Batf2 KO infection models with CCL5 blockade and rescue","pmids":["37724373","36824275"],"confidence":"High","gaps":["How interferon signaling drives BATF2 transcription mechanistically not shown"]},{"year":2025,"claim":"Provided direct genomic evidence that BATF2 occupies cell-cycle and IRF1 regulatory regions in astrocytes, unifying its growth-suppressive and IFN-restraining roles.","evidence":"ChIP-seq in astrocytes, BATF2 KO astrocytes and Batf2-/- EAE mice, proliferation marker Western blotting, MS lesion immunofluorescence","pmids":["40945729","40057949"],"confidence":"High","gaps":["Whether BATF2 binds these loci directly or via partner factors not resolved","Cofactors at IRF1 regulatory regions unidentified"]},{"year":2025,"claim":"Linked a specific phosphorylation event (Ser227) to STING oligomerization and a metabolism-dependent type-I IFN anti-tumor response.","evidence":"Phospho-site mutagenesis, STING oligomerization assays, metabolic profiling, syngeneic and carcinogen-induced HNSCC Batf2-/- models","pmids":["41457098"],"confidence":"Medium","gaps":["Kinase responsible for Ser227 phosphorylation unknown","Single study"]},{"year":null,"claim":"How BATF2 selects between transcriptional activation, AP-1 sequestration, and direct cytoplasmic protein degradation in different cell types, and which signals govern its nuclear-cytoplasmic partitioning, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of BATF2 DNA or partner binding","Kinase/E3 ligase machinery acting on BATF2 incompletely defined","Direct genome-wide targets across cell types only partially mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,6,18,24]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[18,29]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,7,4]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,15,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,6,7,17,27]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,18,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,9,15,32]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[20,9,3]}],"complexes":[],"partners":["JUN","IRF1","RELA","NFKB1","TP53","ATF3","SINHCAF","STAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N1L9","full_name":"Basic leucine zipper transcriptional factor ATF-like 2","aliases":["Suppressor of AP-1 regulated by IFN","SARI"],"length_aa":274,"mass_kda":29.4,"function":"AP-1 family transcription factor that controls the differentiation of lineage-specific cells in the immune system. Following infection, participates in the differentiation of CD8(+) thymic conventional dendritic cells in the immune system. Acts via the formation of a heterodimer with JUN family proteins that recognizes and binds DNA sequence 5'-TGA[CG]TCA-3' and regulates expression of target genes (By similarity). Selectively suppresses CCN1 transcription and hence blocks the downstream cell proliferation signals produced by CCN1 and inhibits CCN1-induced anchorage-independent growth and invasion in several cancer types, such as breast cancer, malignant glioma and metastatic melanoma. Possibly acts by interfering with AP-1 binding to CCN1 promoter","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8N1L9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BATF2","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BATF2","total_profiled":1310},"omim":[{"mim_id":"614983","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 2; BATF2","url":"https://www.omim.org/entry/614983"},{"mim_id":"612476","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE; BATF","url":"https://www.omim.org/entry/612476"},{"mim_id":"612470","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 3; BATF3","url":"https://www.omim.org/entry/612470"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BATF2"},"hgnc":{"alias_symbol":["MGC20410","SARI"],"prev_symbol":[]},"alphafold":{"accession":"Q8N1L9","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N1L9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N1L9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N1L9-F1-predicted_aligned_error_v6.png","plddt_mean":61.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BATF2","jax_strain_url":"https://www.jax.org/strain/search?query=BATF2"},"sequence":{"accession":"Q8N1L9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N1L9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N1L9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N1L9"}},"corpus_meta":[{"pmid":"25957166","id":"PMC_25957166","title":"Batf2/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25957166","citation_count":89,"is_preprint":false},{"pmid":"27353863","id":"PMC_27353863","title":"SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27353863","citation_count":85,"is_preprint":false},{"pmid":"32650804","id":"PMC_32650804","title":"m6A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling.","date":"2020","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32650804","citation_count":83,"is_preprint":false},{"pmid":"19074269","id":"PMC_19074269","title":"Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN).","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19074269","citation_count":81,"is_preprint":false},{"pmid":"31174572","id":"PMC_31174572","title":"Calycosin suppresses TGF-β-induced epithelial-to-mesenchymal transition and migration by upregulating BATF2 to target PAI-1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31174572","citation_count":48,"is_preprint":false},{"pmid":"24282278","id":"PMC_24282278","title":"Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24282278","citation_count":46,"is_preprint":false},{"pmid":"20531301","id":"PMC_20531301","title":"Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20531301","citation_count":45,"is_preprint":false},{"pmid":"28808017","id":"PMC_28808017","title":"Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28808017","citation_count":44,"is_preprint":false},{"pmid":"25706880","id":"PMC_25706880","title":"Epidemiology of severe acute respiratory illness (SARI) among adults and children aged ≥5 years in a high HIV-prevalence setting, 2009-2012.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25706880","citation_count":44,"is_preprint":false},{"pmid":"25762344","id":"PMC_25762344","title":"BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25762344","citation_count":41,"is_preprint":false},{"pmid":"30771439","id":"PMC_30771439","title":"Targeted demethylation of the SARI promotor impairs colon tumour growth.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30771439","citation_count":40,"is_preprint":false},{"pmid":"23049725","id":"PMC_23049725","title":"The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23049725","citation_count":40,"is_preprint":false},{"pmid":"28356392","id":"PMC_28356392","title":"BATF2 inhibits immunopathological Th17 responses by suppressing Il23a expression during Trypanosoma cruzi infection.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28356392","citation_count":38,"is_preprint":false},{"pmid":"26376615","id":"PMC_26376615","title":"Targeting Batf2 for infectious diseases and cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26376615","citation_count":37,"is_preprint":false},{"pmid":"34812424","id":"PMC_34812424","title":"Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.","date":"2021","source":"The Lancet. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/34812424","citation_count":37,"is_preprint":false},{"pmid":"36635421","id":"PMC_36635421","title":"MANF ameliorates DSS-induced mouse colitis via restricting Ly6ChiCX3CR1int macrophage transformation and suppressing CHOP-BATF2 signaling pathway.","date":"2023","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/36635421","citation_count":31,"is_preprint":false},{"pmid":"21399589","id":"PMC_21399589","title":"Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran.","date":"2010","source":"Tropical biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/21399589","citation_count":29,"is_preprint":false},{"pmid":"37781029","id":"PMC_37781029","title":"CD36-BATF2\\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37781029","citation_count":28,"is_preprint":false},{"pmid":"33452462","id":"PMC_33452462","title":"BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33452462","citation_count":28,"is_preprint":false},{"pmid":"30542107","id":"PMC_30542107","title":"Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases.","date":"2018","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30542107","citation_count":26,"is_preprint":false},{"pmid":"28739720","id":"PMC_28739720","title":"Inhibition of Bevacizumab-induced Epithelial-Mesenchymal Transition by BATF2 Overexpression Involves the Suppression of Wnt/β-Catenin Signaling in Glioblastoma Cells.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28739720","citation_count":25,"is_preprint":false},{"pmid":"18392087","id":"PMC_18392087","title":"Biochemistry of pyrethroid resistance in German cockroach (Dictyoptera, Blatellidae) from hospitals of Sari, Iran.","date":"2007","source":"Iranian biomedical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18392087","citation_count":21,"is_preprint":false},{"pmid":"30753547","id":"PMC_30753547","title":"BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway.","date":"2019","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30753547","citation_count":20,"is_preprint":false},{"pmid":"32166887","id":"PMC_32166887","title":"miRNA-765 mediates multidrug resistance via targeting BATF2 in gastric cancer cells.","date":"2020","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/32166887","citation_count":20,"is_preprint":false},{"pmid":"26808579","id":"PMC_26808579","title":"SARI, a novel target gene of glucocorticoid receptor, plays an important role in dexamethasone-mediated killing of B lymphoma cells.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26808579","citation_count":18,"is_preprint":false},{"pmid":"31140101","id":"PMC_31140101","title":"BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/β-catenin signaling.","date":"2019","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/31140101","citation_count":17,"is_preprint":false},{"pmid":"29394132","id":"PMC_29394132","title":"Decrease in invasion of HTR-8/SVneo trophoblastic cells by interferon gamma involves cross-communication of STAT1 and BATF2 that regulates the expression of JUN.","date":"2018","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/29394132","citation_count":16,"is_preprint":false},{"pmid":"35949109","id":"PMC_35949109","title":"m6A modification-mediated BATF2 suppresses metastasis and angiogenesis of tongue squamous cell carcinoma through inhibiting VEGFA.","date":"2022","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35949109","citation_count":15,"is_preprint":false},{"pmid":"35246006","id":"PMC_35246006","title":"Bone marrow mesenchymal stem cells-derived exosomes suppress miRNA-5189-3p to increase fibroblast-like synoviocyte apoptosis via the BATF2/JAK2/STAT3 signaling pathway.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35246006","citation_count":15,"is_preprint":false},{"pmid":"37289427","id":"PMC_37289427","title":"Establishing severe acute respiratory infection (SARI) surveillance in a sentinel hospital, Ireland, 2021 to 2022.","date":"2023","source":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/37289427","citation_count":15,"is_preprint":false},{"pmid":"21892628","id":"PMC_21892628","title":"Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.","date":"2011","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21892628","citation_count":15,"is_preprint":false},{"pmid":"22256409","id":"PMC_22256409","title":"Age-specific seroprevalence of hepatitis A in Sari, northern Islamic Republic of Iran.","date":"2011","source":"Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit","url":"https://pubmed.ncbi.nlm.nih.gov/22256409","citation_count":15,"is_preprint":false},{"pmid":"31549215","id":"PMC_31549215","title":"BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells.","date":"2019","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31549215","citation_count":14,"is_preprint":false},{"pmid":"36824275","id":"PMC_36824275","title":"BATF2 promotes HSC myeloid differentiation by amplifying IFN response mediators during chronic infection.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36824275","citation_count":14,"is_preprint":false},{"pmid":"39629124","id":"PMC_39629124","title":"BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/β-catenin pathway.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/39629124","citation_count":13,"is_preprint":false},{"pmid":"26135942","id":"PMC_26135942","title":"The tumor-suppressive role of BATF2 in esophageal squamous cell carcinoma.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26135942","citation_count":13,"is_preprint":false},{"pmid":"33732022","id":"PMC_33732022","title":"Circ_0005927 Inhibits the Progression of Colorectal Cancer by Regulating miR-942-5p/BATF2 Axis.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33732022","citation_count":13,"is_preprint":false},{"pmid":"38862817","id":"PMC_38862817","title":"ABBV-744 alleviates LPS-induced neuroinflammation via regulation of BATF2-IRF4-STAT1/3/5 axis.","date":"2024","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38862817","citation_count":12,"is_preprint":false},{"pmid":"37777155","id":"PMC_37777155","title":"BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non-small cell lung cancer.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37777155","citation_count":11,"is_preprint":false},{"pmid":"37724373","id":"PMC_37724373","title":"BATF2 enhances proinflammatory cytokine responses in macrophages and improves early host defense against pulmonary Klebsiella pneumoniae infection.","date":"2023","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37724373","citation_count":11,"is_preprint":false},{"pmid":"19947179","id":"PMC_19947179","title":"Seroprevalence of hepatitis C infection and associated risk factors among addicted prisoners in Sari-Iran.","date":"2009","source":"Pakistan journal of biological sciences : PJBS","url":"https://pubmed.ncbi.nlm.nih.gov/19947179","citation_count":11,"is_preprint":false},{"pmid":"24471558","id":"PMC_24471558","title":"Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.","date":"2014","source":"Hemoglobin","url":"https://pubmed.ncbi.nlm.nih.gov/24471558","citation_count":11,"is_preprint":false},{"pmid":"37151195","id":"PMC_37151195","title":"Nuclear export of BATF2 enhances colorectal cancer proliferation through binding to CRM1.","date":"2023","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37151195","citation_count":10,"is_preprint":false},{"pmid":"33740622","id":"PMC_33740622","title":"BATF2 balances the T cell-mediated immune response of CADM with an anti-MDA5 autoantibody.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33740622","citation_count":10,"is_preprint":false},{"pmid":"23323095","id":"PMC_23323095","title":"Species identification of birds nasal trichobilharzia in sari, north of iran.","date":"2012","source":"Iranian journal of parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/23323095","citation_count":10,"is_preprint":false},{"pmid":"38282047","id":"PMC_38282047","title":"Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38282047","citation_count":9,"is_preprint":false},{"pmid":"34774620","id":"PMC_34774620","title":"SARI inhibits growth and reduces survival of oral squamous cell carcinomas (OSCC) by inducing endoplasmic reticulum stress.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34774620","citation_count":9,"is_preprint":false},{"pmid":"37995570","id":"PMC_37995570","title":"The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37995570","citation_count":8,"is_preprint":false},{"pmid":"31578820","id":"PMC_31578820","title":"SARI suppresses colitis-associated cancer development by maintaining MCP-1-mediated tumour-associated macrophage recruitment.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31578820","citation_count":8,"is_preprint":false},{"pmid":"27326418","id":"PMC_27326418","title":"H1299R in coagulation Factor V and Glu429Ala in MTHFR genes in recurrent pregnancy loss in Sari, Mazandaran.","date":"2016","source":"International journal of reproductive biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/27326418","citation_count":8,"is_preprint":false},{"pmid":"26923243","id":"PMC_26923243","title":"Occurrence of aflatoxin M₁ in commercial pasteurized milk samples in Sari, Mazandaran province, Iran.","date":"2016","source":"Mycotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/26923243","citation_count":8,"is_preprint":false},{"pmid":"39304906","id":"PMC_39304906","title":"High prevalence of HPV-56 and HPV-39 in Sari, Iran: an analysis of genotype distribution.","date":"2024","source":"Virology journal","url":"https://pubmed.ncbi.nlm.nih.gov/39304906","citation_count":7,"is_preprint":false},{"pmid":"36672163","id":"PMC_36672163","title":"Loss of the Immunomodulatory Transcription Factor BATF2 in Humans Is Associated with a Neurological Phenotype.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36672163","citation_count":6,"is_preprint":false},{"pmid":"28875005","id":"PMC_28875005","title":"Iron Profile and Inflammatory Status of Overweight and Obese Women in Sari, North of Iran.","date":"2017","source":"International journal of hematology-oncology and stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28875005","citation_count":6,"is_preprint":false},{"pmid":"26221484","id":"PMC_26221484","title":"Inhibition of janus kinase 2 by compound AG490 suppresses the proliferation of MDA-MB-231 cells via up-regulating SARI (suppressor of AP-1, regulated by IFN).","date":"2015","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26221484","citation_count":6,"is_preprint":false},{"pmid":"25848389","id":"PMC_25848389","title":"Cryptosporidium infection in patients with gastroenteritis in sari, iran.","date":"2014","source":"Iranian journal of parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/25848389","citation_count":6,"is_preprint":false},{"pmid":"20973399","id":"PMC_20973399","title":"Assessment of coagulation state and its related factors in thalassemia intermedia patients referred to thalassemia research center at Booali Sina Hospital Sari/IR Iran in 2007.","date":"2010","source":"Pakistan journal of biological sciences : PJBS","url":"https://pubmed.ncbi.nlm.nih.gov/20973399","citation_count":6,"is_preprint":false},{"pmid":"40057949","id":"PMC_40057949","title":"BATF2 is a regulator of interferon-γ signaling in astrocytes during neuroinflammation.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40057949","citation_count":5,"is_preprint":false},{"pmid":"26977016","id":"PMC_26977016","title":"Discovery of a Regulatory Motif for Human Satellite DNA Transcription in Response to BATF2 Overexpression.","date":"2016","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26977016","citation_count":5,"is_preprint":false},{"pmid":"34227806","id":"PMC_34227806","title":"Promotion Effect of EGCG on the Raised Expression of IL-23 through the Signaling of STAT3-BATF2-c-JUN/ATF2.","date":"2021","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34227806","citation_count":5,"is_preprint":false},{"pmid":"22321784","id":"PMC_22321784","title":"[Expression and significance of SARI and CCN1 in human colorectal carcinomas].","date":"2011","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/22321784","citation_count":5,"is_preprint":false},{"pmid":"36077244","id":"PMC_36077244","title":"Blood RNA Sequencing Indicates Upregulated BATF2 and LY6E and Downregulated ISG15 and MT2A Expression in Children with Autism Spectrum Disorder.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36077244","citation_count":4,"is_preprint":false},{"pmid":"26339361","id":"PMC_26339361","title":"Expression and mechanism of action of the SARI tumor suppressor in prostate cancer.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26339361","citation_count":4,"is_preprint":false},{"pmid":"38252354","id":"PMC_38252354","title":"Epidemic profile of common respiratory viruses in association SARS CoV-2 among SARI and ARI-two year study.","date":"2024","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/38252354","citation_count":4,"is_preprint":false},{"pmid":"32368555","id":"PMC_32368555","title":"First Report of Biochemical Mechanisms of Insecticide Resistance in the Field Population of Culex pipiens (Diptera: Culicidae) from Sari, Mazandaran, North of Iran.","date":"2019","source":"Journal of arthropod-borne diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32368555","citation_count":4,"is_preprint":false},{"pmid":"40442751","id":"PMC_40442751","title":"Targeting BATF2-RGS2 axis reduces T-cell exhaustion and restores anti-tumor immunity.","date":"2025","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40442751","citation_count":3,"is_preprint":false},{"pmid":"39672395","id":"PMC_39672395","title":"BATF2/SINHCAF regulates the quantity and function of macrophages infected with Mycobacterium Tuberculosis via regulation of TTC23 through Wnt/β-catenin pathway.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39672395","citation_count":3,"is_preprint":false},{"pmid":"38724525","id":"PMC_38724525","title":"Genomic characterization of Influenza A (H1N1)pdm09 and SARS-CoV-2 from Influenza Like Illness (ILI) and Severe Acute Respiratory Illness (SARI) cases reported between July-December, 2022.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38724525","citation_count":3,"is_preprint":false},{"pmid":"36660762","id":"PMC_36660762","title":"Seroepidemiology of HBV, HCV, HIV, HTLV, and CMV in Pregnant Women Referring to Sari Birth Cohort.","date":"2022","source":"Advanced biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/36660762","citation_count":3,"is_preprint":false},{"pmid":"25568563","id":"PMC_25568563","title":"Prevalence and genotypes of hepatitis B virus infection in patients underwent coronary angiography and coronary artery bypass grafting in mazandaran heart center, sari, iran.","date":"2014","source":"Medical archives (Sarajevo, Bosnia and Herzegovina)","url":"https://pubmed.ncbi.nlm.nih.gov/25568563","citation_count":3,"is_preprint":false},{"pmid":"30061803","id":"PMC_30061803","title":"Study on the Quality of Life Among the Cancer Patients at the Sari Comprehensive Cancer Center in 2017.","date":"2018","source":"Materia socio-medica","url":"https://pubmed.ncbi.nlm.nih.gov/30061803","citation_count":3,"is_preprint":false},{"pmid":"34961433","id":"PMC_34961433","title":"Frequency of blaIMP and blaSPM Metallo-β-Lactamase Genes among Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolates in Sari, North of Iran.","date":"2021","source":"Recent advances in anti-infective drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34961433","citation_count":3,"is_preprint":false},{"pmid":"40267724","id":"PMC_40267724","title":"The BATF2-ATF3 axis exacerbates intervertebral disc degeneration via inducing mitochondrial dysfunction.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40267724","citation_count":2,"is_preprint":false},{"pmid":"27739031","id":"PMC_27739031","title":"Effects and mechanisms of action of SARI on androgen-independent prostate cancer (DU145) cells.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27739031","citation_count":2,"is_preprint":false},{"pmid":"37870740","id":"PMC_37870740","title":"Clinical Profile, Intensive Care Needs and Predictors of Outcome Among Children Admitted with Non-COVID Severe Acute Respiratory Illness (SARI) During the Pandemic.","date":"2023","source":"Indian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/37870740","citation_count":2,"is_preprint":false},{"pmid":"41457098","id":"PMC_41457098","title":"BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41457098","citation_count":1,"is_preprint":false},{"pmid":"39071355","id":"PMC_39071355","title":"BATF2 is a regulator of interferon-γ signaling in astrocytes during neuroinflammation.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39071355","citation_count":1,"is_preprint":false},{"pmid":"25779069","id":"PMC_25779069","title":"[The expression and clinical significance of BATF2 in oral tongue squamous cell carcinoma].","date":"2015","source":"Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology","url":"https://pubmed.ncbi.nlm.nih.gov/25779069","citation_count":1,"is_preprint":false},{"pmid":"39504573","id":"PMC_39504573","title":"Role of the basic leucine zipper transcription factor BATF2 in modulating immune responses and inflammation in health and disease.","date":"2025","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/39504573","citation_count":1,"is_preprint":false},{"pmid":"22097096","id":"PMC_22097096","title":"Evaluation of serum C-reactive protein level and its related factors in hemodialysis patients in Sari, Iran.","date":"2011","source":"Pakistan journal of biological sciences : PJBS","url":"https://pubmed.ncbi.nlm.nih.gov/22097096","citation_count":1,"is_preprint":false},{"pmid":"31938099","id":"PMC_31938099","title":"Endogenous SARI exerts oncogenic functions in human K562 leukemia cells by targeting the PI3K/Akt/mTOR and NF-κB signaling pathways.","date":"2018","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31938099","citation_count":1,"is_preprint":false},{"pmid":"40945729","id":"PMC_40945729","title":"BATF2-mediated control of astrocyte proliferation.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40945729","citation_count":0,"is_preprint":false},{"pmid":"42059142","id":"PMC_42059142","title":"BATF2 reverses multidrug resistance of gastric cancer cells and centrosome clustering by suppressing ATM phosphorylation.","date":"2026","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/42059142","citation_count":0,"is_preprint":false},{"pmid":"42139975","id":"PMC_42139975","title":"Shenfu decoction attenuates radiation-induced heart disease by modulating the P53-MDM2 complex and the STAT1-BATF2 axis.","date":"2026","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42139975","citation_count":0,"is_preprint":false},{"pmid":"26117008","id":"PMC_26117008","title":"[Biological Effects of the SARI Over-expression on K562 Cell Line].","date":"2015","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/26117008","citation_count":0,"is_preprint":false},{"pmid":"31418351","id":"PMC_31418351","title":"[Effect of SARI Overexpression on Apoptosis of CBFL Cells and Its Mechanism].","date":"2019","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31418351","citation_count":0,"is_preprint":false},{"pmid":"36705277","id":"PMC_36705277","title":"Effectiveness of vero cell inactivated vaccine against severe acute respiratory infections (SARI) in Sibu, Malaysia: A retrospective test-negative design.","date":"2023","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36705277","citation_count":0,"is_preprint":false},{"pmid":"21867603","id":"PMC_21867603","title":"[Influence of BCR-ABL inhibitor STI571 on SARI expression in K562 cells].","date":"2011","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/21867603","citation_count":0,"is_preprint":false},{"pmid":"37940513","id":"PMC_37940513","title":"Immune response evaluation after Sputnik V vaccination in Sari healthcare population.","date":"2023","source":"The journal of medical investigation : JMI","url":"https://pubmed.ncbi.nlm.nih.gov/37940513","citation_count":0,"is_preprint":false},{"pmid":"42169608","id":"PMC_42169608","title":"Genomic and Molecular Characterisation of Respiratory Syncytial Virus in the National SARI Surveillance System Across Three Consecutive Seasons in North Macedonia (2022-2025).","date":"2026","source":"Acta medica academica","url":"https://pubmed.ncbi.nlm.nih.gov/42169608","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48836,"output_tokens":7956,"usd":0.132924,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17461,"output_tokens":4598,"usd":0.101127,"stage2_stop_reason":"end_turn"},"total_usd":0.234051,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"BATF2/SARI is an IFN-beta-inducible gene that interacts with c-Jun via its leucine zipper domain, inhibiting DNA binding of the AP-1 complex and consequently suppressing AP-1-dependent gene expression; overexpression induces apoptosis in cancer cells but not normal cells.\",\n      \"method\": \"Co-immunoprecipitation (leucine zipper interaction with c-Jun), AP-1 reporter assays, antisense knockdown, overexpression in cancer vs. normal cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, reporter assay, antisense KD, functional rescue) in a single foundational study, replicated conceptually in multiple subsequent papers\",\n      \"pmids\": [\"19074269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BATF2/SARI inhibits AP-1 transactivation by interacting with c-Jun and directly suppresses CCN1 promoter activity; SARI overexpression reduces CCN1-promoter AP-1 binding and inhibits anchorage-independent growth and tumor cell invasion.\",\n      \"method\": \"Adenoviral overexpression (Ad.SARI), promoter-activity luciferase assays, AP-1 binding assays, stable c-Jun-overexpressing rat embryo fibroblast epistasis model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (promoter assay, AP-1 binding, genetic epistasis), single lab\",\n      \"pmids\": [\"20531301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BATF2 forms a complex with IRF1; Co-IP demonstrated this association, and IRF1 knockdown down-regulated IFN-γ- or LPS-activated host-protective genes (Tnf, Ccl5, Il12b, Nos2), indicating BATF2/IRF1 co-regulation of M1 macrophage inflammatory gene expression.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, expression profiling, promoter motif enrichment analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional knockdown with defined gene-expression phenotype, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"25957166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BATF2 overexpression inhibits HGF/MET signaling in colorectal cancer cells, suppressing proliferation, migration, and invasion; MET inhibitors combined with IFN-β produced synergistic cytotoxicity in vitro and in vivo.\",\n      \"method\": \"Overexpression in cultured CRC cells, xenograft tumor models, in vitro/in vivo combination treatment assays\",\n      \"journal\": \"Clinical cancer research : an official journal of the American Association for Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and xenograft functional assays with defined signaling pathway, single lab\",\n      \"pmids\": [\"25762344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BATF2/SARI directly interacts with ceruloplasmin (Cp) and induces its protease degradation, thereby inhibiting the HIF-1α/VEGF axis and suppressing tumor angiogenesis.\",\n      \"method\": \"Co-IP/PAGE/mass spectrometry, HUVEC angiogenesis assays, antibody arrays, in vivo AOM/DSS tumor model in SARI-deficient mice\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Co-IP/MS for direct interaction identification, multiple functional assays in vitro and in vivo with genetic knockout model\",\n      \"pmids\": [\"27353863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BATF2/SARI expression is necessary for mda-7/IL-24 anti-tumor effects; MDA-7/IL-24 induces SARI through p38 MAPK phosphorylation, and inhibition of p38 MAPK blocks SARI induction; secreted MDA-7/IL-24 induces its own expression via an autocrine loop involving SARI.\",\n      \"method\": \"SARI antisense inhibition, adenoviral overexpression, p38 MAPK inhibitor experiments, recombinant MDA-7/IL-24 stimulation, receptor binding studies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antisense loss-of-function plus pharmacological pathway inhibition, single lab\",\n      \"pmids\": [\"24282278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BATF2 interacts with NF-κB p50/p65 subunits and promotes IL-12 p40 expression in macrophages; BATF2-deficient macrophages produce significantly less IL-12 p40 upon TLR ligand stimulation, reducing CD8+ T cell activation within tumors.\",\n      \"method\": \"Co-immunoprecipitation (BATF2 with p50/p65), Batf2-/- mouse model, in vitro macrophage stimulation assays, subcutaneous tumor model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus Batf2 KO mouse model with defined immune phenotype, replicated in vitro and in vivo\",\n      \"pmids\": [\"28808017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BATF2 interacts with c-JUN and prevents c-JUN–ATF-2 complex formation in innate immune cells, thereby inhibiting Il23a expression and suppressing IL-17-mediated immunopathology during T. cruzi infection.\",\n      \"method\": \"Batf2-/- mouse infection model, co-immunoprecipitation (BATF2/c-JUN), cytokine measurement, T cell transfer experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP for mechanism plus Batf2 KO mouse model with defined immunological phenotype and rescue experiments\",\n      \"pmids\": [\"28356392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Glucocorticoid receptor (GR) directly binds the ER9 element in the SARI promoter region, activating SARI transcription; SARI upregulation is necessary for dexamethasone-mediated growth suppression and AP-1 inhibition in B lymphoma cells.\",\n      \"method\": \"EMSA, ChIP assays, reporter assays, SARI siRNA knockdown, in vitro and in vivo dexamethasone treatment\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — EMSA and ChIP establish direct GR-promoter binding; functional knockdown confirms necessity; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"26808579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BATF2 binds p53 protein and enhances its stability, thereby inhibiting ERK phosphorylation in gastric cancer cells; additionally, METTL3-mediated m6A modification of BATF2 mRNA represses BATF2 expression in gastric cancer.\",\n      \"method\": \"Co-immunoprecipitation (BATF2-p53), Western blotting for p53 stability and p-ERK levels, m6A modification assays, in vitro and in vivo functional experiments\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and protein stability assays plus pathway inhibition, single lab\",\n      \"pmids\": [\"32650804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BATF2 suppresses the STAT1/MCP-1/CCR2 axis in colon cancer cells: SARI deficiency increases p-STAT1 and STAT1 expression, promotes MCP-1 secretion, and enhances tumor-associated macrophage infiltration during colitis-associated cancer.\",\n      \"method\": \"SARI-deficient mouse model, bone marrow reconstitution, Western blotting for p-STAT1, functional tumor macrophage infiltration assays\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO mouse plus mechanistic Western blotting, single lab\",\n      \"pmids\": [\"31578820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BATF2 targets PAI-1 (plasminogen activator inhibitor-1), as shown by Co-IP and luciferase assays; BATF2 induction by calycosin suppresses TGF-β-induced EMT and cell migration via the Wnt and PI3K/Akt signaling pathways in CRC cells.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assays, Transwell migration assays, Western blotting\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP and reporter assays establish BATF2-PAI-1 interaction, functional migration assays, single lab\",\n      \"pmids\": [\"31174572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BATF2 overexpression suppresses Wnt/β-catenin signaling and reverses multidrug resistance in gastric cancer cells; knockdown of β-catenin mimics BATF2 effects, and restoration of Wnt/β-catenin activity reverses BATF2-mediated drug sensitization.\",\n      \"method\": \"Overexpression/knockdown systems, Wnt/β-catenin reporter (TOP/FOP FLASH implied), Western blotting, MTT assay, flow cytometry\",\n      \"journal\": \"In vitro cellular & developmental biology. Animal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — epistasis via β-catenin knockdown rescue, Western blot pathway analysis, single lab\",\n      \"pmids\": [\"31140101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of SARI/BATF2 expression initiates epithelial-mesenchymal transition (EMT) in lung adenocarcinoma, characterized by repression of E-cadherin and upregulation of vimentin; SARI regulates EMT through the GSK-3β/β-catenin signaling pathway.\",\n      \"method\": \"SARI knockdown in human carcinoma cells, xenograft mouse model for lymph node metastasis, Western blotting for EMT markers and pathway components\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with defined EMT phenotype and pathway component analysis, in vivo xenograft validation, single lab\",\n      \"pmids\": [\"23049725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BATF2 and STAT1 expression are mutually dependent in trophoblast cells; BATF2 silencing increases invasion, and both BATF2 and STAT1 regulate phospho-JUN expression, jointly mediating IFN-γ-induced inhibition of HTR-8/SVneo trophoblast invasion.\",\n      \"method\": \"siRNA knockdown of BATF2 and STAT1, Transwell invasion assays, NGS expression profiling, Western blotting\",\n      \"journal\": \"Cell adhesion & migration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with defined invasion phenotype and mutual dependency established, single lab\",\n      \"pmids\": [\"29394132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BATF2 nuclear export is mediated through a functional nuclear export sequence (NES) that binds CRM1 (exportin-1); cytoplasmic BATF2 is subsequently targeted for ubiquitin-mediated degradation and enhances CRC growth via AP-1/cyclin D1/pRb signaling. Mutation of NES or CRM1 knockdown retards export and suppresses tumor growth.\",\n      \"method\": \"Co-IP, quantitative label-free LC-MS/MS proteomics, Western blotting, immunofluorescence, point mutation of NES, siRNA knockdown of CRM1, xenograft nude mice\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Co-IP/MS for binding partner identification, NES mutagenesis establishing functional site, CRM1 KD rescue, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"37151195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BATF2 forms a complex with JUN in hematopoietic stem cells (HSCs) to amplify pro-inflammatory signaling including CCL5; CCL5 receptor blockade phenocopies Batf2 KO myeloid differentiation defects, and recombinant CCL5 rescues IFN-γ-induced myeloid differentiation in Batf2 KO mice.\",\n      \"method\": \"Co-IP (BATF2-JUN complex), Batf2 KO mouse model during chronic infection, CCL5 receptor blockade/recombinant CCL5 rescue experiments\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP plus genetic KO with pharmacological rescue, replicated in vivo and in vitro, multiple methods\",\n      \"pmids\": [\"36824275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Induction of BATF2 expression in macrophages by Klebsiella pneumoniae requires TRIF and type I interferon signaling but not MyD88; BATF2 markedly enhances macrophage pro-inflammatory cytokine responses and contributes to early host defense against pulmonary infection.\",\n      \"method\": \"TRIF-/-, MyD88-/-, type I IFN signaling-deficient macrophage experiments in vitro; Batf2-/- mouse Kp infection model\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic pathway dissection using multiple KO cell lines/mice, in vivo Batf2-/- model with bacterial burden and cytokine phenotype\",\n      \"pmids\": [\"37724373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BATF2 binds regulatory regions of cell cycle genes (CDKR1B/p27, CDK2, cyclin D1) in astrocytes as determined by ChIP-seq; BATF2 loss increases expression of these targets and increases proliferation markers (Ki67, phospho-histone H3), establishing BATF2 as a cell cycle suppressor in astrocytes.\",\n      \"method\": \"Chromatin immunoprecipitation sequencing (ChIP-seq), BATF2 KO astrocytes, Western blotting for proliferation markers, patient-derived glioblastoma sample analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP-seq establishes direct genomic binding with loss-of-function confirmation of target gene upregulation, multiple orthogonal methods\",\n      \"pmids\": [\"40945729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In astrocytes, BATF2 binds and prevents overexpression of IRF1 and IRF1 targets (e.g., caspase-1) as shown by ChIP-seq; Batf2-/- mice show exacerbated CNS autoimmune disease severity with increased astrocyte IRF1 and caspase-1 expression.\",\n      \"method\": \"ChIP-seq, Batf2-/- mouse EAE model, immunofluorescence in MS patient lesions, Western blotting\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP-seq for direct binding plus Batf2 KO mouse model with defined neuro-inflammatory phenotype and human tissue validation\",\n      \"pmids\": [\"40057949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BATF2 phosphorylation at serine 227 promotes oligomerization of STING; BATF2 deficiency or high glutamine levels result in higher oxygen consumption rates and metabolic profiles unfavorable for type I interferon production; cancer cell-specific BATF2 expression promotes a type-I IFN-dependent anti-tumor response.\",\n      \"method\": \"Phosphorylation site mutational analysis, STING oligomerization assays, metabolic profiling, syngeneic orthotopic and carcinogen-induced HNSCC models with Batf2-/- mice\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-site mutagenesis and STING oligomerization established; metabolic and in vivo data, single study\",\n      \"pmids\": [\"41457098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BATF2 inhibits SDF-1α/CXCL12 expression intracellularly, reducing its loading into extracellular vesicles; BATF2-containing EVs inhibit MDSC chemotaxis in vitro, and blocking SDF-1α/CXCR4 signaling phenocopies BATF2 overexpression in reducing MDSC recruitment to glioblastoma.\",\n      \"method\": \"BATF2 overexpressing glioma cell EV isolation, in vitro MDSC chemotaxis assays, AMD3100 (CXCR4 antagonist) blockade, Western blotting for SDF-1α\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological blockade phenocopies BATF2 OE; EV-based mechanism, functional chemotaxis assay; single lab\",\n      \"pmids\": [\"33452462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BATF2/SARI induces cancer-specific cell death in OSCC by inhibiting GLI1 expression through induction of endoplasmic reticulum (ER) stress; an ER stress inhibitor reverses SARI-mediated tumor growth inhibition in vivo.\",\n      \"method\": \"Adenoviral SARI overexpression (Ad.SARI), confocal microscopy for ER stress markers, ER stress inhibitor rescue, xenograft nude mouse model\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ER stress pathway placement via pharmacological inhibitor rescue in vitro and in vivo, single lab\",\n      \"pmids\": [\"34774620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BATF2 interacts with SINHCAF and together they regulate TTC23 transcription; this regulation modulates macrophage quantity and anti-bacterial/antigen-presenting function during Mycobacterium tuberculosis infection through the Wnt/β-catenin pathway.\",\n      \"method\": \"Co-immunoprecipitation (BATF2-SINHCAF), TTC23 knockdown/overexpression, Wnt/β-catenin pathway inhibition, macrophage functional assays\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP establishes BATF2-SINHCAF complex; functional pathway placement via KD, single lab\",\n      \"pmids\": [\"39672395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BATF2 transcriptionally regulates RGS2 in CD8+ T cells; BATF2 KO mice show increased effector CD8+ T cells and reduced exhausted T cells; luciferase reporter assays confirmed BATF2 as a transcriptional activator of RGS2, promoting T cell exhaustion through inhibition of CXCL13 secretion.\",\n      \"method\": \"Luciferase reporter assays for RGS2 promoter, BATF2-/- and RGS2-/- mouse tumor models, single-cell transcriptomics, CD8+ T cell co-culture cytotoxicity assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter establishes transcriptional regulation; KO mouse models with defined immune phenotype; single lab\",\n      \"pmids\": [\"40442751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL14-mediated m6A modification of BATF2 mRNA suppresses BATF2 expression in tongue squamous cell carcinoma; BATF2 suppresses tumor angiogenesis by inhibiting VEGFA expression.\",\n      \"method\": \"m6A methylation assays, METTL14 knockdown/overexpression, Western blotting for VEGFA, angiogenesis assays in TSCC cell lines\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — m6A writer identified and functional VEGFA downstream target established; single lab\",\n      \"pmids\": [\"35949109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BATF2 inhibits ABCG2 drug transporter expression and promotes PTEN stability, suppressing AKT phosphorylation, reducing nuclear β-catenin, and decreasing stem cell markers (CD44, SOX2, NANOG) to reduce chemoresistance in gastric cancer.\",\n      \"method\": \"BATF2 overexpression/KD in GC cells and organoids, Western blotting for PTEN/AKT/β-catenin pathway, ABCG2 expression assays, in vivo subcutaneous tumor model, scRNA-seq\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway components analyzed with OE/KD, in vivo validation, single lab\",\n      \"pmids\": [\"39629124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss-of-function homozygous BATF2 mutation (p.Gln19*) in humans causes dysregulation of interferon-stimulated genes and elevated innate immune responses; CRISPR-Cas9 BATF2-/- human monocytic cell lines recapitulate elevated responses to innate immune stimuli.\",\n      \"method\": \"Whole-exome sequencing, transcriptome analysis, CRISPR-Cas9 BATF2-/- human monocytic cell lines, stimulation assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — human genetics plus CRISPR KO cell line functional validation, transcriptomic phenotyping; multiple orthogonal methods\",\n      \"pmids\": [\"36672163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BATF2 stabilizes ATF3 by inhibiting its ubiquitination; BATF2 overexpression impairs mitochondrial redox homeostasis in nucleus pulposus cells, promoting apoptosis and ECM catabolism; ATF3 knockdown reverses BATF2-induced mitochondrial dysfunction.\",\n      \"method\": \"Ubiquitination assays for ATF3, BATF2 overexpression/KD in nucleus pulposus cells, mitochondrial function assays, ATF3 siRNA rescue, in vivo disc degeneration model\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay establishes post-translational mechanism; ATF3 KD rescue confirms pathway placement; single lab\",\n      \"pmids\": [\"40267724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BATF2 overexpression drives transcription of centromeric type II satellite DNA; ChIP-seq identified a specific DNA binding motif (TTCCATT[CT]GATTCCATTC[AG]AT) primarily distributed among chromosome centromere regions.\",\n      \"method\": \"Stable BATF2 transfection in HeLa cells, ChIP-sequencing, bioinformatics motif analysis, satellite DNA transcription assays\",\n      \"journal\": \"Anticancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — ChIP-seq establishes genomic binding motif; single lab, single method study\",\n      \"pmids\": [\"26977016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BATF2 promotes Th1 and Treg cell differentiation but suppresses Th17 cell activation in CD4+ T cells; BATF2 mRNA is increased under Th1 and Treg polarization conditions but decreased under Th17 polarization.\",\n      \"method\": \"siRNA knockdown of BATF2 in human CD4+ T cells, cytokine polarization conditions, flow cytometry for T cell subsets\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with defined T cell polarization phenotype; single lab\",\n      \"pmids\": [\"33740622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ABBV-744 (BD2-selective BET inhibitor) reduces BATF2 and IRF4 expression and suppresses JAK-STAT signaling in LPS-stimulated microglia; gene knockdown of BATF2 confirmed BATF2 is required for the BATF2-IRF4-STAT1/3/5 pathway regulation of microglial inflammation.\",\n      \"method\": \"RNA-seq, BATF2/IRF4 siRNA knockdown, Western blotting for STAT1/3/5, in vitro BV-2 and primary microglia models, in vivo mouse LPS model\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene KD confirmation of pathway; RNA-seq; single lab\",\n      \"pmids\": [\"38862817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BATF2 inhibits PD-L1 expression in cancer cells by inhibiting the PI3K-AKT pathway, with ZEB2 playing an important role in this process; BATF2 promotes CD8+ T cell infiltration and activation in non-small cell lung cancer.\",\n      \"method\": \"BATF2 KO mice, human xenograft mice, RT-qPCR, Western blotting, bioinformatics analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse plus xenograft model with defined pathway; single lab\",\n      \"pmids\": [\"37777155\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BATF2 (also known as SARI) is an IFN-β/IFN-γ-inducible basic leucine zipper transcription factor that acts as a tumor suppressor and immune regulator: it suppresses AP-1 activity by interacting with c-Jun via its leucine zipper domain, forms functional complexes with IRF1, NF-κB (p50/p65), and JUN to regulate macrophage inflammatory gene programs (including IL-12p40, TNF, CCL5, NOS2), undergoes nuclear export via a CRM1-dependent NES sequence followed by ubiquitin-mediated degradation in cancer cells, binds and stabilizes p53 to inhibit ERK signaling, promotes STING oligomerization when phosphorylated at Ser227, directly targets ceruloplasmin for degradation to inhibit the HIF-1α/VEGF angiogenic axis, and is transcriptionally regulated by glucocorticoid receptor binding to its promoter and post-transcriptionally silenced by METTL3/METTL14-mediated m6A modification; in innate immune cells it suppresses IL-23 production by preventing c-JUN–ATF2 complex formation, and in astrocytes it binds IRF1 regulatory regions to prevent overactive IFN signaling and controls cell cycle gene expression including cyclin D1, CDK2, and p27.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BATF2 (SARI) is an interferon-inducible basic leucine zipper transcription factor that functions as a tumor suppressor and an immune regulator by reprogramming AP-1-dependent and interferon-dependent gene expression [#0, #2]. Its founding activity is antagonism of AP-1: BATF2 binds c-Jun through its leucine zipper domain, blocking AP-1 DNA binding and transactivation, repressing AP-1 targets such as CCN1, and triggering cancer-cell-selective apoptosis [#0, #1]. In innate immune cells BATF2 partners with transcriptional and signaling factors to shape inflammatory output \\u2014 it complexes with IRF1 to co-regulate M1 macrophage genes (Tnf, Ccl5, Il12b, Nos2), with NF-\\u03baB p50/p65 to drive IL-12p40 and CD8+ T cell activation, and with JUN to amplify pro-inflammatory CCL5 signaling, while preventing c-JUN\\u2013ATF2 complex formation to restrain Il23a and IL-17-mediated immunopathology [#2, #6, #7, #16]. Its induction in macrophages is interferon-driven, requiring TRIF and type I IFN signaling, and human loss-of-function (p.Gln19*) dysregulates interferon-stimulated genes [#17, #27]; in astrocytes BATF2 directly occupies IRF1 regulatory regions by ChIP-seq to prevent overactive IFN signaling and protect against CNS autoimmunity [#19]. Beyond transcriptional partnerships, BATF2 acts post-translationally \\u2014 it directly binds ceruloplasmin and drives its degradation to suppress the HIF-1\\u03b1/VEGF angiogenic axis, binds and stabilizes p53 to inhibit ERK signaling, and when phosphorylated at Ser227 promotes STING oligomerization to favor a type-I-IFN-dependent anti-tumor response [#4, #9, #20]. As a sequence-specific factor BATF2 binds defined genomic motifs and represses cell-cycle genes (cyclin D1, CDK2, p27) in astrocytes [#18, #29]. BATF2 protein abundance is itself controlled: glucocorticoid receptor binds the SARI promoter to activate transcription, while m6A modification by METTL3/METTL14 silences BATF2 mRNA in gastric and tongue cancers, and a CRM1-dependent NES drives nuclear export followed by ubiquitin-mediated degradation in colorectal cancer [#8, #9, #15, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established BATF2's founding molecular activity \\u2014 that an IFN-inducible bZIP factor antagonizes AP-1 \\u2014 answering how it could act as a tumor suppressor.\",\n      \"evidence\": \"Co-IP of leucine-zipper interaction with c-Jun, AP-1 reporter assays, antisense knockdown and overexpression in cancer versus normal cells\",\n      \"pmids\": [\"19074269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define direct genomic targets of BATF2 itself\", \"Mechanism of cancer-cell-selective apoptosis unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected AP-1 antagonism to a specific target promoter and tumor phenotype, showing BATF2 suppresses CCN1 and anchorage-independent growth.\",\n      \"evidence\": \"Adenoviral overexpression, CCN1 promoter luciferase and AP-1 binding assays, c-Jun-overexpressing fibroblast epistasis\",\n      \"pmids\": [\"20531301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCN1 repression is direct or via AP-1 sequestration not separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed loss of BATF2 promotes EMT and metastasis via GSK-3\\u03b2/\\u03b2-catenin, framing it as a metastasis suppressor.\",\n      \"evidence\": \"Knockdown in carcinoma cells, xenograft lymph node metastasis model, EMT marker Western blotting\",\n      \"pmids\": [\"23049725\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct evidence BATF2 regulates GSK-3\\u03b2/\\u03b2-catenin components transcriptionally\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified IRF1 as a transcriptional partner, establishing BATF2 as a co-regulator of the M1 macrophage inflammatory program.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, expression profiling and promoter motif enrichment in macrophages\",\n      \"pmids\": [\"25957166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DNA-binding contribution of BATF2 versus IRF1 at target promoters not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a non-transcriptional mechanism \\u2014 direct binding and degradation of ceruloplasmin \\u2014 linking BATF2 to suppression of the HIF-1\\u03b1/VEGF angiogenic axis.\",\n      \"evidence\": \"Co-IP/MS, HUVEC angiogenesis assays, antibody arrays, AOM/DSS tumor model in SARI-deficient mice\",\n      \"pmids\": [\"27353863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease responsible for ceruloplasmin degradation not identified\", \"How a nuclear bZIP factor reaches ceruloplasmin unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined upstream transcriptional control by glucocorticoid receptor, explaining how steroid signaling induces BATF2 to suppress growth.\",\n      \"evidence\": \"EMSA and ChIP showing GR binding to the SARI promoter ER9 element, reporter assays, siRNA knockdown with dexamethasone treatment\",\n      \"pmids\": [\"26808579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GR induction of BATF2 occurs outside B lymphoma cells not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided the first direct genomic binding map, showing BATF2 recognizes a centromeric satellite-associated motif.\",\n      \"evidence\": \"Stable transfection in HeLa, ChIP-seq and motif analysis\",\n      \"pmids\": [\"26977016\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of satellite DNA transcription unclear\", \"Single-method study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established two distinct immune partnerships: NF-\\u03baB-dependent promotion of IL-12p40 anti-tumor immunity and JUN-dependent restraint of pathogenic IL-23/IL-17.\",\n      \"evidence\": \"Co-IP with p50/p65 and with c-JUN, Batf2-/- mice, macrophage stimulation, tumor and T. cruzi infection models\",\n      \"pmids\": [\"28808017\", \"28356392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BATF2 switches between activating (NF-\\u03baB) and repressive (JUN/ATF2) modes not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified p53 stabilization as a mechanism of ERK inhibition and revealed m6A as a post-transcriptional silencing layer in gastric cancer.\",\n      \"evidence\": \"Co-IP, p53 stability and p-ERK Western blotting, m6A modification assays in gastric cancer\",\n      \"pmids\": [\"32650804\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect link between p53 binding and ERK suppression unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined nuclear export and degradation as the route to BATF2 inactivation in cancer, identifying CRM1 as the export receptor.\",\n      \"evidence\": \"Co-IP/LC-MS proteomics, NES point mutation, CRM1 knockdown, immunofluorescence, xenografts\",\n      \"pmids\": [\"37151195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating cytoplasmic BATF2 degradation not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected human BATF2 loss-of-function to dysregulated interferon-stimulated gene control, establishing a physiological brake on innate immunity.\",\n      \"evidence\": \"Whole-exome sequencing of p.Gln19* patients, CRISPR-Cas9 BATF2-/- human monocytic lines with stimulation assays\",\n      \"pmids\": [\"36672163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical disease spectrum of the mutation not fully delineated\", \"Direct ISG targets in human cells not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed interferon-pathway dependence of BATF2 induction (TRIF/type I IFN, not MyD88) and a JUN-CCL5 axis amplifying inflammation in hematopoietic cells.\",\n      \"evidence\": \"TRIF/MyD88/IFN-deficient macrophages, Co-IP of BATF2-JUN, Batf2 KO infection models with CCL5 blockade and rescue\",\n      \"pmids\": [\"37724373\", \"36824275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How interferon signaling drives BATF2 transcription mechanistically not shown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided direct genomic evidence that BATF2 occupies cell-cycle and IRF1 regulatory regions in astrocytes, unifying its growth-suppressive and IFN-restraining roles.\",\n      \"evidence\": \"ChIP-seq in astrocytes, BATF2 KO astrocytes and Batf2-/- EAE mice, proliferation marker Western blotting, MS lesion immunofluorescence\",\n      \"pmids\": [\"40945729\", \"40057949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BATF2 binds these loci directly or via partner factors not resolved\", \"Cofactors at IRF1 regulatory regions unidentified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked a specific phosphorylation event (Ser227) to STING oligomerization and a metabolism-dependent type-I IFN anti-tumor response.\",\n      \"evidence\": \"Phospho-site mutagenesis, STING oligomerization assays, metabolic profiling, syngeneic and carcinogen-induced HNSCC Batf2-/- models\",\n      \"pmids\": [\"41457098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase responsible for Ser227 phosphorylation unknown\", \"Single study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BATF2 selects between transcriptional activation, AP-1 sequestration, and direct cytoplasmic protein degradation in different cell types, and which signals govern its nuclear-cytoplasmic partitioning, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of BATF2 DNA or partner binding\", \"Kinase/E3 ligase machinery acting on BATF2 incompletely defined\", \"Direct genome-wide targets across cell types only partially mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 6, 18, 24]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [18, 29]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 7, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 15, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 6, 7, 17, 27]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 18, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 9, 15, 32]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [20, 9, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"JUN\", \"IRF1\", \"RELA\", \"NFKB1\", \"TP53\", \"ATF3\", \"SINHCAF\", \"STAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}